The Alteration of HDL Protein Composition in Patients With Coronary Heart Disease Before and After Statins Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01543308|
Recruitment Status : Unknown
Verified May 2013 by Yan Li-rong, Chinese Academy of Medical Sciences, Fuwai Hospital.
Recruitment status was: Active, not recruiting
First Posted : March 2, 2012
Last Update Posted : May 20, 2013
The protein composition of HDL is complicated. The investigators have identified 40 distinct proteins associated with HDL by proteomics technology, and these proteins have been confirmed to be related to the function of anti-inflammation, anti-oxidation, improvement of endothelial function, inhibition of thrombosis and so on. And the investigators also found that the levels of some proteins in HDL changed in patients with coronary heart disease, compared with the healthy control group.
So, this study is to conduct in the two following aspects: enlarge the sample size to verify the preliminary results to find new research ideas of pathogenesis and biomarkers for coronary heart disease; and study the changes of HDL protein composition in patients with coronary heart disease before and after statins treatment using proteomics technology in order to find the mechanism of statins pleiotropic effects and indicators for evaluating the treatment effectiveness.
|Condition or disease|
|Coronary Heart Disease|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Observational Model:||Case Control|
|Official Title:||Phase 1 Study of Coronary Heart Disease Proteomics Research|
|Study Start Date :||February 2012|
|Estimated Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||December 2015|
|coronary heart disease|
|healthy control group|
- Differential Proteins and the levels of Differential Proteins [ Time Frame: up to 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01543308
|Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, FuWai Hospital|
|Beijing, China, 100037|
|Principal Investigator:||Hong Liu||FuWai Hospital|